A. S. Levashov, S. Zagidullina, T. T. Valiev, A. Stroganova, Dmitry A. Khochenkov, V. Grigorenko, E. V. Mikhaylova, Elizaveta V. Tyurina, M. Ryzhova, Serhii Horielyshev, Shavkat U. Kadyrov, V. Polyakov
{"title":"在治疗 3 岁以上髓母细胞瘤患儿方面采用 SJMB 方案的国际经验(文献综述)","authors":"A. S. Levashov, S. Zagidullina, T. T. Valiev, A. Stroganova, Dmitry A. Khochenkov, V. Grigorenko, E. V. Mikhaylova, Elizaveta V. Tyurina, M. Ryzhova, Serhii Horielyshev, Shavkat U. Kadyrov, V. Polyakov","doi":"10.26442/18151434.2023.3.202437","DOIUrl":null,"url":null,"abstract":"During the last 30 years, unique international experience has been accumulated in the treatment of children with medulloblastoma, especially in the age group over 3 years. Evolutionary representations about one of the most well – known international protocols – SJMB (in versions since 1996 – SJMB96, since 2003 – SJMB03, since 2012 – SJMB12) are shown in this article. Innovative criteria for stratifying patients into risk groups were established according to clinical, therapeutic, morphological and molecular-biological prognostic factors. Despite the accumulated experience, it is necessary to continue studying the relationship between age groups and the molecular biology of tumor cells for the purpose of subsequent optimization of the treatment program.","PeriodicalId":16401,"journal":{"name":"Journal of Modern Oncology","volume":"5 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"International experience by using of the SJMB protocols in treatment of children with medulloblastoma in the age group over 3 years (literature review)\",\"authors\":\"A. S. Levashov, S. Zagidullina, T. T. Valiev, A. Stroganova, Dmitry A. Khochenkov, V. Grigorenko, E. V. Mikhaylova, Elizaveta V. Tyurina, M. Ryzhova, Serhii Horielyshev, Shavkat U. Kadyrov, V. Polyakov\",\"doi\":\"10.26442/18151434.2023.3.202437\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"During the last 30 years, unique international experience has been accumulated in the treatment of children with medulloblastoma, especially in the age group over 3 years. Evolutionary representations about one of the most well – known international protocols – SJMB (in versions since 1996 – SJMB96, since 2003 – SJMB03, since 2012 – SJMB12) are shown in this article. Innovative criteria for stratifying patients into risk groups were established according to clinical, therapeutic, morphological and molecular-biological prognostic factors. Despite the accumulated experience, it is necessary to continue studying the relationship between age groups and the molecular biology of tumor cells for the purpose of subsequent optimization of the treatment program.\",\"PeriodicalId\":16401,\"journal\":{\"name\":\"Journal of Modern Oncology\",\"volume\":\"5 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Modern Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.26442/18151434.2023.3.202437\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Modern Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/18151434.2023.3.202437","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
International experience by using of the SJMB protocols in treatment of children with medulloblastoma in the age group over 3 years (literature review)
During the last 30 years, unique international experience has been accumulated in the treatment of children with medulloblastoma, especially in the age group over 3 years. Evolutionary representations about one of the most well – known international protocols – SJMB (in versions since 1996 – SJMB96, since 2003 – SJMB03, since 2012 – SJMB12) are shown in this article. Innovative criteria for stratifying patients into risk groups were established according to clinical, therapeutic, morphological and molecular-biological prognostic factors. Despite the accumulated experience, it is necessary to continue studying the relationship between age groups and the molecular biology of tumor cells for the purpose of subsequent optimization of the treatment program.